Business
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
About this update from Cg Oncology, Inc.
[{"type":"text","content":"Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). They include: Patrick Hensley, MD, University of Kentucky Research FoundationDevelopment of an artificial intelligence powered prognostic biomarker for intravesical cretostimogene in BCG unresponsive non-muscle invasive bladder cancer Daniel Joyce, MD, MS, Vanderbilt University Medical CenterProviding individualized price transparency at the point of care for patients with BCG-unresponsive non-muscle-invasive bladder cancer Additionally, the 2025 NMIBC Research Fellowship grant recipients presented their research at the SUO 2026 Annual Meeting at the AUA. The details of their presentations are as follows: Taylor A. Goodstein, MD, Emory University Spatial transcriptomic profiling of the tumor microenvironment in BCG-unresponsive NMIBC patients treated with novel intravesical gene therapies Saum B. Ghodoussipour, MD, Rutgers Cancer Institute of New JerseyDynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer “Partnering with the SUO-CTC on this fellowship reflects our shared commitment to advancing care for patients with bladder cancer,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “By supporting innovative research and fostering collaboration, this program helps accelerate progress toward meaningful breakthroughs that can make a lasting difference for patients.” Drs. Goodstein and Ghodoussipour share...